This is the authors' abstract. We don't add key points for this paper.
Background: Liver cancer remains a major global health concern, necessitating exploration of alternative therapeutic agents. Visha Bilvadi Agada , a classical Ayurvedic polyherbal formulation containing sixteen herbal ingredients, is enriched with phytoconstituents possessing reported anticancer, antioxidant, anti-inflammatory, and radioprotective activities, suggesting its potential role in hepatocellular carcinoma management. Therefore, the present study was undertaken to evaluate the anticancer potential of Visha Bilvadi Agada against the HepG2 hepatic cancer cell line using the sulforhodamine B (SRB) assay. Materials and Methods: HepG2 cells were cultured in Dulbecco’s Modified Eagle Medium high glucose supplemented with 10% fetal bovine serum and maintained at 37°C in 5% CO 2 . The cells were seeded at a density of 15,000 cells/well in 96-well plates and treated with serial concentrations (100–1000 μg/mL) of the test sample for 24 h. The cell viability was assessed by the SRB assay, and percentage inhibition was calculated relative to untreated controls. Doxorubicin served as the standard drug. Results: Visha Bilvadi Agada demonstrated dose-dependent cytotoxicity. Maximum inhibition of 79.9% was observed at 1000μg/mL, while minimum inhibition of 19.0% was seen at 100 μg/mL. The IC 50 value was calculated as 513 μg/mL. In contrast, doxorubicin exhibited 75% inhibition at 2.5 μM with significantly higher potency (half maximal inhibitory concentration: 0.00091 μM). Conclusion: Visha Bilvadi Agada exhibits moderate in vitro antiproliferative activity against HepG2 cells.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kapdi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: